A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Public ClinicalTrials.gov record NCT06623422. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Study identification
- NCT ID
- NCT06623422
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 680 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Cisplatin Drug
- Carboplatin Drug
- Pemetrexed Drug
- Gemcitabine Drug
- Paclitaxel Drug
- Intismeran autogene Biological
- Placebo Other
Biological · Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 20, 2024
- Primary completion
- May 15, 2033
- Completion
- Jan 25, 2038
- Last update posted
- Aug 26, 2026
2024 – 2038
United States locations
- U.S. sites
- 52
- U.S. states
- 20
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center ( Site 0181) | Gilbert | Arizona | 85234 | Recruiting |
| The University of Arizona Cancer Center - North Campus ( Site 0163) | Tucson | Arizona | 85719 | Recruiting |
| Providence St. Jude Medical Center ( Site 0106) | Fullerton | California | 92835 | Recruiting |
| VA Long Beach Healthcare System ( Site 0199) | Long Beach | California | 90822 | Recruiting |
| USC Norris Comprehensive Cancer Center ( Site 0205) | Los Angeles | California | 90033 | Recruiting |
| UCLA Jonsson Comprehensive Cancer Center ( Site 0135) | Los Angeles | California | 90404 | Recruiting |
| UCSF Medical Center at Mission Bay ( Site 0178) | San Francisco | California | 94158 | Recruiting |
| University of Colorado Anschutz Medical Campus ( Site 0151) | Aurora | Colorado | 80045 | Recruiting |
| UCHealth Memorial Hospital Central ( Site 0125) | Colorado Springs | Colorado | 80909 | Recruiting |
| Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207) | Greeley | Colorado | 80631 | Recruiting |
| Centura Health - St. Anthony North Health Campus ( Site 0189) | Westminster | Colorado | 80023 | Recruiting |
| Yale University School of Medicine ( Site 0201) | New Haven | Connecticut | 06510 | Recruiting |
| Eastern CT Hematology & Oncology Associates ( Site 0202) | Norwich | Connecticut | 06360 | Recruiting |
| The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156) | Fort Lauderdale | Florida | 33316 | Recruiting |
| Miami Cancer Institute at Baptist Health, Inc. ( Site 0214) | Miami | Florida | 33176 | Recruiting |
| Beacon Cancer Care ( Site 0127) | Post Falls | Idaho | 83854 | Recruiting |
| The University of Chicago Medical Center ( Site 0118) | Chicago | Illinois | 60637 | Recruiting |
| Franciscan Health ( Site 0219) | Indianapolis | Indiana | 46237 | Recruiting |
| Maryland Oncology Hematology (MOH) ( Site 8102) | Rockville | Maryland | 20850 | Recruiting |
| Massachusetts General Hospital ( Site 0136) | Boston | Massachusetts | 02114 | Recruiting |
| Dana Farber Cancer Hospital ( Site 0155) | Boston | Massachusetts | 02215 | Recruiting |
| Ellis Fischel Cancer Center ( Site 0133) | Columbia | Missouri | 65212 | Completed |
| Lake Regional Hospital-Cancer Center ( Site 0123) | Osage Beach | Missouri | 65065 | Completed |
| Roswell Park Cancer Institute ( Site 0184) | Buffalo | New York | 14263 | Recruiting |
| Hematology-Oncology Associates of CNY ( Site 0164) | East Syracuse | New York | 13057 | Recruiting |
| The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216) | New York | New York | 10011 | Recruiting |
| Icahn School of Medicine at Mount Sinai ( Site 0116) | New York | New York | 10029 | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 0137) | New York | New York | 10065 | Recruiting |
| SUNY Upstate Cancer Center ( Site 0140) | Syracuse | New York | 13210 | Recruiting |
| Montefiore Medical Center ( Site 0160) | The Bronx | New York | 10461 | Recruiting |
| Westchester Medical Center ( Site 0196) | Valhalla | New York | 10595 | Recruiting |
| Novant Health Weisiger Cancer Insititute ( Site 0266) | Charlotte | North Carolina | 28204 | Recruiting |
| Novant Health Forsyth Medical Center ( Site 0166) | Winston-Salem | North Carolina | 27103 | Recruiting |
| University of Cincinnati Medical Center ( Site 0119) | Cincinnati | Ohio | 45219 | Recruiting |
| Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0217) | Corvallis | Oregon | 97330 | Recruiting |
| St. Lukes Hospital and Health Network ( Site 0186) | Bethlehem | Pennsylvania | 18015 | Recruiting |
| Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315) | Chattanooga | Tennessee | 37403 | Recruiting |
| Thompson Cancer Survival Center ( Site 0168) | Knoxville | Tennessee | 37916 | Recruiting |
| Elliston Place Medical Oncology & Hematology ( Site 0215) | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - DFW ( Site 8103) | Dallas | Texas | 75246 | Recruiting |
| UT Southwestern Medical Center ( Site 0190) | Dallas | Texas | 75390 | Recruiting |
| Houston Methodist Cancer Center ( Site 0191) | Houston | Texas | 77030 | Recruiting |
| MD Anderson Cancer Center ( Site 0150) | Houston | Texas | 77030 | Recruiting |
| Memorial Hermann Cancer Center ( Site 0172) | Houston | Texas | 77030 | Recruiting |
| Michael E. DeBakey VA Medical Center ( Site 0197) | Houston | Texas | 77030 | Recruiting |
| O'Quinn Medical Tower at McNair Campus ( Site 0131) | Houston | Texas | 77030 | Recruiting |
| The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148) | Tyler | Texas | 75701 | Recruiting |
| Virginia Cancer Specialists ( Site 0167) | Fairfax | Virginia | 22031 | Recruiting |
| Virginia Oncology Associates (VOA) ( Site 8101) | Norfolk | Virginia | 23502 | Recruiting |
| VCU Health Adult Outpatient Pavillion ( Site 0193) | Richmond | Virginia | 23219 | Recruiting |
| Swedish Cancer Institute ( Site 0143) | Seattle | Washington | 98104 | Recruiting |
| St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192) | Silverdale | Washington | 98383 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 189 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06623422, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06623422 live on ClinicalTrials.gov.